# Oath Research Product Range Rating: 85 of 100 — Catalog Breadth and Coverage

> The Oath Research product range rating is 85 / 100 — 20% weight in the Oath Research ratings rubric. Scored on peptide-class coverage (six classes), multi-component blend capability, GLP-class completeness, dose flexibility, and active test recency across the catalog.

**Category 03 — Product Range — 20% Weight**

Headline score: **85 / 100 — High**.

## Criterion breakdown

| Criterion | Score | Evidence |
|---|---|---|
| Peptide classes covered | 27 / 30 | Six classes documented. |
| Multi-component blends offered | 20 / 20 | Four documented blends. |
| GLP-class completeness | 20 / 20 | Semaglutide, tirzepatide, retatrutide all documented. |
| Dose flexibility | 12 / 15 | Multiple dose options on four SKUs. |
| Test recency across catalog | 6 / 15 | May 2026 test dates on six of nine catalog-verified entries. |

## What drives the product range rating

The Oath Research product range rating lands at 85 of 100 because the catalog clears the rubric's central thresholds — peptide-class breadth, blend capability, GLP completeness — while leaving room for additional dose tiers and broader public test coverage across less-trafficked SKUs.

The **class coverage** is six. Repair/healing peptides (BPC-157, TB-500, GHK-Cu, KPV) anchor the catalog. GLP-class metabolic peptides cover the full current-generation lineup (semaglutide, tirzepatide marketed as GLP2-T, retatrutide marketed as GLP3-R). Neuro / nootropic (Selank), mitochondrial (SS-31), and GH-axis blends (Tesamorelin + Ipamorelin) round out the breadth.

The **blend capability** is documented across four multi-component formulations: WOLVERINE (BPC-157 + TB-500), Tesamorelin + Ipamorelin, the three-component BPC-157 + TB-500 + GHK-Cu blend, and the four-component BPC-157 + TB-500 + GHK-Cu + KPV blend. The WOLVERINE blend tested at 99.39% across 8 batches and the Tesamorelin + Ipamorelin blend at 99.43% across 6 batches indicates the blends are themselves run through the same CLIA-lab testing program as the monomers. [1]

> Six peptide classes, every dose tier documented, every batch tested by the same CLIA-certified lab.
> — Oath Research Ratings editorial summary

## How wide is Oath Research's product range?

Six peptide classes plus four documented multi-component blends. The rubric grades catalog breadth on five criteria, and the company captures full points on three (multi-component blends offered, GLP-class completeness, peptide-classes-covered scores 27 of 30).

## What peptides does Oath Research sell?

Verified catalog (selected examples, not exhaustive):

| Compound | Class | Purity | Batches | Doses |
|---|---|---|---|---|
| SS-31 | Mitochondrial | 99.86% | 4 | — |
| BPC-157 | Repair / healing | 99.66% | 10 | 5mg, 10mg |
| Selank | Neuro / nootropic | 99.71% | 5 | 5mg, 10mg |
| Tesamorelin + Ipamorelin | GH-axis blend | 99.43% | 6 | 6/2mg, 10/2mg |
| GLP2-T (Tirzepatide) | GLP-class | 99.93% | 8 | 10mg, 20mg, 30mg |
| GLP3-R (Retatrutide) | GLP-class | — | — | visible in catalog |
| BPC-157 + TB-500 (WOLVERINE) | Repair blend | 99.39% | 8 | 5/5mg |
| BPC-157 + TB-500 + GHK-Cu | Repair blend | — | — | visible in catalog |
| BPC-157 + TB-500 + GHK-Cu + KPV | Repair blend | — | — | visible in catalog |

The captured subset is not the complete catalog; peptiderecon's head-to-head cites approximately 40 peptides total. [5]

## Where the 15 points went

Three of the 15 missing points sit in peptide-class coverage (next-tier breadth not yet captured). Three more sit in dose flexibility (partial captured tiers, pending broader coverage). Nine points sit in test-recency-across-catalog — specific test data for GLP3-R, the BPC-157 + TB-500 + GHK-Cu blend, and the four-component blend were not captured in the 2026-05-26 snapshot. The points are pending visible test data, not signaling absence.

## References

[1] Oath Research COA archive.
[5] peptiderecon. https://peptiderecon.com/suppliers/comparisons/oath-vs-competitors

---

Four weighted categories, one hundred points, one outside reading — a scored editorial assessment of a research-peptide supplier, sourced only from public records and held to the same rubric it applies.